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Abstract
Malignant Pleural Mesothelioma (MPM) is an aggressive cancer that is often diagnosed at an advanced stage and is
characterized by a long latency period (20–40 years between initial exposure and diagnosis) and prior exposure to asbestos.
Currently accurate diagnosis of MPM is difficult due to the lack of sensitive biomarkers and despite minor improvements in
treatment, median survival rates do not exceed 12 months. Accumulating evidence suggests that aberrant expression of
long non-coding RNAs (lncRNAs) play an important functional role in cancer biology. LncRNAs are a class of recently
discovered non-protein coding RNAs .200 nucleotides in length with a role in regulating transcription. Here we used
NCode long noncoding microarrays to identify differentially expressed lncRNAs potentially involved in MPM pathogenesis.
High priority candidate lncRNAs were selected on the basis of statistical (P,0.05) and biological significance (.3-fold
difference). Expression levels of 9 candidate lncRNAs were technically validated using RT-qPCR, and biologically validated in
three independent test sets: (1) 57 archived MPM tissues obtained from extrapleural pneumonectomy patients, (2) 15
cryopreserved MPM and 3 benign pleura, and (3) an extended panel of 10 MPM cell lines. RT-qPCR analysis demonstrated
consistent up-regulation of these lncRNAs in independent datasets. ROC curve analysis showed that two candidates were
able to separate benign pleura and MPM with high sensitivity and specificity, and were associated with nodal metastases
and survival following induction chemotherapy. These results suggest that lncRNAs have potential to serve as biomarkers in
MPM.
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Introduction
Malignant Pleural Mesothelioma (MPM) is an aggressive cancer
often diagnosed at an advanced stage and characterized by a long
latency period (vis. 20–60 years) [1]. Currently, the differential
diagnosis of MPM is difficult and panels of biomarkers and expert
pathologists are often needed to arrive at a definite diagnosis.
Median survival rates do not exceed 12–18 months following
initial diagnosis and the effect of modestly improved chemother-
apy is difficult to recognise [2,3]. Thus new diagnostic and
treatment approaches are urgently needed. The identification of
novel diagnostic and prognostic biomarkers is expected to help
improve the management of MPM patients.
In order to identify biomarkers and novel therapeutic targets for
MPM, a better understanding of MPM biology is required. To this
end, much work has focused on mRNA expression profiles and
DNA copy number changes in MPM, with microRNA profiling a
more recent addition. In contrast, there is little known about the
role of long non-coding RNAs (lncRNAs) in MPM. LncRNAs, a
class of recently discovered non-protein coding RNAs .200
nucleotides in length, have been found to control every level of
gene expression, including post-transcriptional gene regulation via
control of protein synthesis, RNA maturation and regulation of
chromatin structure, as well as mediation of transcription factor
activity [4]. Wang et. al. have suggested the presence of four
molecular functions for lncRNAs – as signals, decoys, guides and
scaffolds [4]. As signalling molecules, lncRNAs can respond to
specific stimuli in a time specific manner, and as such can act as
markers of functionally and biologically important events (re-
viewed in [4]). Secondly, lncRNAs can regulate transcription by
acting as independent decoys which negatively regulate effector
proteins. As guides, lncRNAs can direct changes in gene
expression in either cis (neighbouring) or trans (distantly located)
genes and finally can act as molecular scaffolds. More recently,
Gutschner et al suggested eight molecular functions of lncRNAs,
these being; regulators of gene expression, sponges which sequester
microRNAs preventing inhibition of their target transcripts [5],
modulators of protein activity and localisation, as endo-siRNAs
that target other RNAs for target degradation, as regulators of
alternative splicing, scaffolds and finally as important controllers of
chromatin remodelling and histone modifications [6].
Altered expression of lncRNAs has been implicated in a myriad
of biological processes including normal tissue development and
cancer. Accumulating evidence suggests that their aberrant
expression plays important functional roles in cancer biology.
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For example high expression of metastasis associated lung
adenocarcinoma transcript 1 (MALAT1) has been associated with
metastases and poor outcome in patients with NSCLC [7,8], and
is thought to have an important role in alternative splicing and
pre-mRNA processing [9]. Similarly, the Hox transcript antisense
intergenic RNA (HOTAIR) has been shown to interact with the
polycomb repressor complex, and is important in epigenetic
control. Up-regulation of this lncRNA has been implicated in
breast cancer metastasis [10], tumour recurrence in hepatocellular
carcinoma [11] and can regulate PTEN methylation in laryngeal
squamous cell carcinoma [12]. Taken together, these studies attest
to the value of lncRNAs as potential markers and potential targets
for therapeutic intervention.
Here we have investigated the role of lncRNAs in MPM
biology, by (1) comparing lncRNA expression profiles between
MPM cell lines and the normal immortalized human mesothelial
cell line (MeT-5A) and selecting candidate lncRNAs found to be
differentially expressed, (2) validated expression of these lncRNAs
in MPM cell lines and an independent set of MPM tumours and
(3) correlated lncRNA expression with nodal metastasis and
overall survival.
Methods
Ethics Statement
This project was approved by the Human Research Ethics
Committees at Concord Repatriation General Hospital (Sydney)
and the St. James’ Hospital/The Adelaide & Meath Hospital
(Dublin). All subjects gave informed written consent at the time of
surgery for donation of their tissue for this research.
Unpublished de novo cell lines were created at the Institute of
Cancer Research Vienna from patient material obtained during
surgical biopsy at the Division of Thoracic Surgery, Comprehen-
sive Cancer Center, Medical University of Vienna. Tissue banking
and processing to cell lines was approved by the Ethical Review
Board of the Medical University of Vienna and General Hospital
Vienna AKH (approval number EK Nr. 904/2009). All patients
gave informed written consent for use of their tissue in this
research.
Cell lines and clinical samples
Human mesothelioma cell lines H28, H226, H2052, H2452
and MSTO obtained from the American Type Cell Culture
repository (ATCC, Rockville, USA), MM05 (kindly provided by
the UQ Thoracic Research Centre, The Prince Charles Hospital,
Brisbane [13]) VMC6, VMC6/52A, VMC20, VMC40, VMC23
(kindly provided by Walter Berger, Institute of Cancer Research
and Walter Klepetko, Division of Thoracic Surgery, Medical
University of Vienna, Austria [14,15]) were all grown in RPMI
with 10% fetal bovine serum (FBS) at 37uC with 5% CO2. CLAB
and 1988 were kindly provided by Melotti et. al and grown in
supplemented medium as previously published [16] (70% MCDB
201,30% DMEM, 2% FBS, 2nM clutamine, 1% penicillin/
streptomycin, 10 ng/mL bFGF, 20 ng/ml EGF, 15 mg/ml
insulin, 2 mg/ml Heparin). REN cells were obtained from Steven
Albeda [17] and grown in Ham’s F12 medium. Cells from the
normal human mesothelial line MeT-5A were obtained from the
ATCC and grown in DMEM with 10% FBS. All medium, FBS
and other supplements were obtained from Life Technologies or
Sigma. The MPM cell lines consisted of a combination of
epithelioid (VMC20, VMC23, VMC6, H226, H28, REN, H2052,
H2452, 1988, CLAB) and biphasic (VMC40, MM05, MSTO-
211H) subtypes.
The formalin-fixed paraffin embedded (FFPE) tumour tissues
used in this study were part of a reported series of extrapleural
pneumonectomy patients collected from the Royal Prince Alfred
Hospital (RPAH) or Strathfield Private Hospital, Sydney between
1994 and 2009 [18]. Molecular subtyping was performed by
formal pathology review (SK). Fresh-frozen mesothelium and
benign pleural samples were also collected following debulking
surgery at Glenfield Hospital Leicester, and were stored in The
Leicestershire Mesothelioma Tissue Bank. All patients gave
informed written consent for inclusion of their tissue in this study.
Anonymised specimens from 18 patients who had not received
preoperative treatment were transferred to St. James’ Hospital,
Dublin. Subject demographics are provided in Table 1.
RNA Isolation
Total RNA was extracted from cell lines using the TRIzol
reagent (Life Technologies, Carlsbad, CA), from formalin-fixed
paraffin embedded (FFPE) tissues using the QIAGEN FFPE
RNeasy kit (Qiagen, Valencia, CA) and from cryopreserved
malignant mesothelium and benign pleura using the TRI reagent
(MRC, Cincinnati, OH) according to manufacturer’s instructions.
Prior to nucleic acid isolation, FFPE tissue sections were marked
and examined by an anatomical pathologist to guide laser-capture
microdissection. RNA quality was assessed using an Agilent 2100
Bioanalyser (Agilent Technologies, Santa Clara, CA) for the
microarray samples and quantified using an Implen Nanophoto-
metre (Implen, Munich, Germany). Samples with RNA integrity
numbers (RINs).8.0 were used for microarray analysis. RNA was
stored at 280uC until further processing.
Microarray Data Acquisition and Pre-processing
Microarray profiling experiments were performed according to
MIAME guidelines using NCode Human Non-coding RNA
microarrays (Life Technologies) representing 17,112 non-coding
RNAs and 22,074 mRNA probes. Briefly, 10mg of total RNA was
labelled using the Superscript Plus Direct cDNA labelling system
(Life Technologies), then hybridised to NCode Noncoding RNA
v1.0 microarrays according to manufacturer’s instructions. After
washing, the slides were stored in liquid N2 gas for scanning within
24 hours. Arrays were scanned using an Agilent scanner (Agilent
Technologies) at the Ramaciotti Centre for Gene Function
Analysis (University of NSW, Sydney, Australia). Data was
Table 1. Subject Demographics of the two independent
validation cohorts.
COHORT 1# COHORT 2*
MPM Control FFPE MPM
N 14 3 57
Median Age (Range) 60.1 (40–75) 55.2 (39–68) 58 (22–74)
Sex (N, %)
Male 11 (78.5) 3 (100) 44 (77.2)
Female 3 (21.5) 0 (0) 13 (22.8)
Histotype (N, %)
Epitheliod 5 (35.7) – 43 (75.4)
Biphasic 6 (42.9) – 14 (24.6)
Sarcomatoid 3 (21.4) – 0 (0)
a*RNA extracted from FFPE for measurement of lncRNA expression; # RNA
extracted from fresh-frozen tumour tissue, control tissue is benign pleura.
doi:10.1371/journal.pone.0070940.t001
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extracted using Agilent Feature Extraction software FE10.5 and
data quality assessed using GeneSpringGX bioinformatics soft-
ware (V12.0, Agilent Technologies). Probes detected in at least one
out of the ten samples were included and baseline transformation
was performed to the sample median. Data was normalised to the
75th percentile. All cell line experiments were performed in
duplicate. All expression data has been deposited in the National
Centre for Biotechnology Information (NCBI) Gene Expression
Omnibus under accession GSE48174.
Quantitative reverse-transcription Polymerase Chain
Reaction (RT-qPCR)
Long noncoding RNA expression levels from microarray
analysis were validated using RT-qPCR in the five cell lines
assayed using NCode microarrays and in a panel of primary and
ATCC-sourced MPM cell lines. In addition, expression levels were
also validated in cryopreserved pleural and mesothelioma tissue
and FFPE MPM tissues. Primers were designed using the
Universal Probe Library (UPL) algorithm provided by Roche
(http://www.roche-applied-science.com/sis/rtpcr/upl/index.
jsp?id =UP030000; See Table 2 for primer sequences). Where
possible, SYBR green primers were designed as close as possible to
the microarray probe to ensure microarray data was reproducible.
In some instances, primers could not be designed to the NCBI
target lncRNA sequence using default settings with UPL and were
not pursued for further analysis. Total RNA (250 ng for cell lines,
50 ng for FFPE and fresh-frozen tissue) was reverse transcribed to
cDNA using the AffinityScript qPCR cDNA synthesis kit (Agilent
Technologies) using a combination of random hexamers (100 ng/
ml) and Oligo (dT) primers (100 ng/ml) in a 10 ml reaction. After
reverse transcription, cDNA was diluted 1:5 with 2 ml of this
product used as template in RT-qPCR using 180nM of forward
and reverse primer. All reactions were run in triplicate on a
Stratagene Mx3000P real-time machine (Agilent Technologies)
using Brilliant II SYBR Green (Agilent Technologies). No
template and no-RT samples were included as negative controls.
All reactions had an initial enzyme inactivation step at 95uC for
10 minutes followed by 40 cycles of 95uC for 15 seconds and 55uC
for 30 seconds. 18S ribosomal RNA was used as the reference for
qPCR data normalisation. Relative expression levels were
calculated using the 2-DDCq method described by Pfaffl [19]
with MeT-5A designated a value of 1 (all fold changes were
calculated relative to this value). Genes were deemed technically
replicated if the direction of expression was consistent with
microarray data and the magnitude of change was greater than 3-
fold.
Identification of an lncRNA prediction panel capable of
distinguishing normal mesothelium and MPM
For the nine candidate lncRNAs identified as being consistently
differentially expressed by RT-qPCR, class prediction analyses
were performed to determine if this panel of lncRNAs could
accurately predict normal/tumour class. All class prediction
analyses were performed in BRB ArrayTools V4.1.0b (developed
by Dr Richard Simon and Amy Peng Lam http://linus.nci.hih.
gov/,brb/tool.htm) using a random variance model developed on
a significance level of P=0.05 [20]. Six different prediction models
were used for classifier development: (1) Compound covariate, (2)
Diagonal linear discriminant analysis, (3) K-nearest neighbour, (4)
Nearest centroid, (5) Support vector machines, and (6) Bayesian
compound covariate model. The misclassification error rate was
predicted using a leave-one out cross-validation (LOOCV)
procedure. In the first instance this predictor was tested using
the microarray data obtained from the NCode microarrays, and
then it was validated using RT-qPCR data obtained from
mesothelioma cell lines and fresh-frozen tissues to confirm overall
sensitivity and specificity.
Gene ontology and Pathway analysis
Over-represented gene ontologies and pathways were deter-
mined using the gene functional annotation tool, forming part of
the DAVID annotation software package (http://david.abcc.
ncifcrf.gov/home.jsp) as described previously [21]. Coding genes
identified as being highly correlated with lncRNA expression were
compared with all genes contained in the DAVID database.
Pathways and gene ontologies with Fisher’s exact probability P-
values less than P=0.05 were considered significantly enriched.
Statistical analyses
Differential microarray expression analysis was performed using
GeneSpring v12.0 using unpaired t-tests. Candidate genes were
selected on the basis of (a) statistical significance of expression
(P,0.05) and (b) magnitude of expression change (.3-fold
difference). For RT-qPCR, gene expression data was analysed
using the Pfaffl method for relative quantitation, and normalised to
18S. Group comparisons, correlations and associations were
performed using SPSS statistical software and two tailed Mann-
Whitney U t-tests. A P-value less than 0.05 was considered
statistically significant. Kaplan-Meier curves and log rank tests
were used to assess survival differences between groups with
multivariate analyses performed to assess the degree of interaction
between different factors. All experiments were performed in
triplicate to ensure reproducibility of results.
Results
LncRNA expression profiles in Malignant Pleural
Mesothelioma (MPM) cell lines
In order to identify new markers for MPM, we used microarrays
to profile lncRNA content in 5 cell lines (4 MPM, and 1 normal
mesothelial cell line). Class comparison analyses were performed
to identify highly differentially expressed lncRNAs in MPM. In
total, this approach identified 44 lncRNAs highly differentially
expressed in MPM cells compared to MeT-5A. Unsupervised
hierarchical cluster analysis demonstrated variations in the
expression profiles of MeT-5A and the four MPM cell lines
(Figure 1a) suggesting the possibility that an lncRNA signature
could exist. After checking the annotations of candidates, eleven
candidates were reclassified as mRNA transcripts and were
excluded, leaving 33 candidate lncRNAs for potential follow-up
(Table 3).
To identify lncRNAs for subsequent experimental analysis, we
further refined our list of lncRNAs by examining their genomic
context in an attempt to better understand the possible functional
role these candidates may have. Previous studies have shown that
many lncRNAs originate from complex transcriptional loci, and
potentially have functional relationships with their nearby coding
genes [22]. The lncRNA-containing loci were grouped into one of
six categories as described by Dinger et. al.: (1) cis-antisense, (2)
intronic, (3) bidirectional, (4) present in the 39UTR, (5) promoter-
associated or (6) intergenic [23]. Of the 33 lncRNAs most
differentially expressed; 22 lncRNAs were intergenic, 3 were
intergenic/bidirectional, 2 cis-antisense, 2 in the 39UTR, 1
bidirectional/cis-antisense, 1 bidirectional only, 1 bidirectional/
39UTR, and 1 that was intronic/promoter associated (Table 3).
Long Non-Coding RNAs in Mesothelioma
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mRNA expression profiles differ between MPM and MeT-
5A cell lines
In addition to the lncRNA content we also profiled mRNA
content using the NCode microarrays. Class comparison analyses
were performed as described for lncRNAs, with high priority
candidates selected on the basis of statistical (P,0.05) and
biological significance (.3-fold change). In total this approach
identified 305 mRNA probes representing 249 genes differentially
expressed between MeT-5A and MPM cell lines: 151 probes were
down-regulated and 155 probes were up-regulated in MPM
compared to MeT-5A. Interrogation of the Oncomine database
identified 28 of these 249 genes in the top 10% under- or
overexpressed genes in MPM compared to normal pleura [24,25]
Some of these genes included ANXA4, GALTN7, MET RBMS1,
TM4SF1, and UCHLI. A list of these genes is provided in Table S1
in File S1. Furthermore, Crispi et. al. identified aberrant
expression of CDKN2A, TK1, MYC and STMN1[26] Further
confirmation in MPM cell lines also confirmed dysregulation of
TSM4SF1, STMN1, IFI16, CDKN3 and ARHGDIG [27]. Gene
ontology analysis of the top 305 mRNA probes revealed over
enrichment of biological processes including cell cycle
(P= 0.0000048), apoptosis (P= 0.00022), cell death (P=0.00029),
cytoskeleton organisation (P= 0.00043), regulation of kinase
activity (P= 0.012), positive regulation of caspase activity
(P= 0.039) and positive regulation of the IkB kinase/NFkB
cascade (P= 0.034). Table S2 in File S1 provides a complete list
of over-enriched gene ontologies.
Technical Validation of Candidate lncRNAs
Next, lncRNA expression was confirmed using RT-qPCR in the
microarray training set consisting of 4 MPM cell lines and the
normal mesothelial line MeT-5A. Primers were successfully
designed for 22 (represented by 23 microarray probes)/33
lncRNAs (33 probes) demonstrating significant differential expres-
sion in MPM cell lines (See Table 2 for primer sequences). For the
remaining 11 candidates, primers could not be successfully
designed using UPL default settings due to the smaller fragment
size. All targets were normalised to 18S. Of the 22 lncRNAs
(represented by 23 probes) assessed, 8 were not detected in any of
the cell lines, 5 did not validate in the correct direction (i.e.
direction of expression was different for microarray and qPCR
data) and 9 lncRNAs were validated. A gene was considered
technically validated if the direction of expression change between
MeT-5A and MPM cell lines was consistent for both microarray
and RT-qPCR and the magnitude of difference was greater than
3-fold.
After normalisation to 18S, the levels for the 14 detectable
lncRNA candidates varied from 1.6-fold to 71.3 fold (Table 3;
Figure 1b). AK130977 and AX746718 were both found to be
down-regulated via both microarray and RT-qPCR (AK130977
Microarray (MA) =25.207, RT-qPCR =21.6; AX746718 MA
=23.37, RT-qPCR =24.6), with AK130977 demonstrating
fairly small changes using RT-qPCR. Similarly, BX648695,
AK129685, EF177379, AK054908, AK130275, AF268386 and
NR_003584 all demonstrated consistent up-regulation using both
microarrays and RT-qPCR.
Table 2. SYBR Green Primer Sequences used for microarray validation of the top 23 lncRNAs identified as being differentially
expressed between MeT-5A mesothelial cells and MPM cell lines.
NCode Probe ID Target ID Chromosomal Position (Hg18) Forward Primer Reverse Primer
IVGNh23506 EF177379 chr11:64949929-64949989 actgtcgttgggatttagagtgt cacaacagcatacccgagac
IVGNh32740 AK130275 chr2:113714740-113714800 ggcagggttaagggaaaaag cagctctggcagaaccactaa
IVGNh25923 AF268386 chr1:161022613-161022673 acaggacacccgaatcaaaa ttcaaataggctgggtatgagg
IVGNh35454 NR_003584 chr4:119420005-119420257 acgatggatgatggaaacataa tccccaactacgataagtcca
IVGNh12568 AK129685 chr19:13810366-13810426 tttgtgaaacgggcagtct cccagcagtgcaacattaaa
IVGNh16972 BC031859 chr16:4551527-4551587 tgctttttagaagccttcatcc ggatgggcagataccagga
IVGNh30904 AX746718 chr17:55867220-55867280 aatgcaatagaaaaagaaaaactcg gggacaaccgaagaaagttg
IVGNh38714 AK054908 chr9:138740661-138741350 ctggacgtctgctcactgg agtccatcacaggcgaagtc
IVGNh37463 BX648695 chr7:124447674-124508032 agctttgtctcgtggagtctg tgtgtaacaagttgcattaaaatcct
IVGNh13194 AK130977 chr20:34612610-34612670 tcagtcccaaacacattctcac atgggtggccagactgag
IVGNh23633 G30815 chr7:30435183-30435243 gcctgattccatattctgtgc cccaatgacggtagatgagg
IVGNh01065 AF056184 chr4:49207176-49207237 tacgctgcacaactggaagt ccgttgaaggactcaaacaga
IVGNh11100 AK126075 chr18:41272277-41281247 caatcacttgagtgaacttgagagt gtgctggacacccagtcag
IVGNh33458 AX746738 chr20:30702313-30702509 cctttacaaaaactggaatgctg ctcgctgagcctttgagg
IVGNh21169 BX648304 chr9:130706223-130706283 caagttttaaatgcctgtgtcaa agaaaggtggcccatcatc
IVGNh12928 AK130470 chr9:14215472-14215532 gcacaagctcaatcattgct tgcagtgagcccagatcc
IVGNh11385 AK126582 chr19:63770592-63770652 cagctctgagcaggtagatgtg gagtggggttcccctatgtc
IVGNh08061 AK094765 chr21:33318726-33319167 agtattttcagtgtcgtctttgtga cggggaagagattagggact
IVGNh24779 U17623 chr21:38693604-38693665 catgggggattgagttcct ggaaccacttctagcaatacagg
IVGNh29716 BC121819 chr15:72560296-72560492 ctcaagtgccgccaaact agccatctgtgtccatagca
IVGNh17420 BC035363 chr8:144866936-144867206 ccataactgcactgccacac caaggaggcgtgtcctca
IVGNh17438 BC035497 chr1:45543009-45543069 tgcagtctctctctttgtgacc gctctgacctggcactctgt
IVGNh09032 AK097452 chr15:78513886-78515514 ctcgtaagatgttgagacttcacc tgacaaagccagagaagagaga
doi:10.1371/journal.pone.0070940.t002
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Analysis of lncRNAs in MPM tumours
lncRNA expression of the nine technically validated targets was
validated in an extended panel of 10 MPM cell lines and
expression calculated relative to the immortalised mesothelial line
MeT-5A. The majority of candidates demonstrated a .3-fold up-
regulation in MPM cell lines compared to MeT-5A (Figure 1c).
For EF177379, MPM cell lines demonstrated a 14.6 fold up-
regulation, with 6/10 cell lines demonstrating .5-fold difference
in expression. High levels were also observed for AK130977
(average 25-fold upregulation; 10/10 cell lines .4-fold differences
in expression) and AF268386 (38-fold upregulation; 7/10 cell lines
.5-fold differences).The remaining candidates AK130275,
AK054908, AK129685 and NR_003584 also demonstrated
moderate levels of up-regulation (3–6 fold) although not all cell
lines demonstrated overexpression.
The expression of the nine targets was then validated in 14
MPM and 3 benign pleura cryopreserved following surgical
resection. All three pleural samples showed no malignancy: Case 1
had benign hyaline plaques with chronic inflammation and
reactive changes (pleural plaques), Case 2 (pneumothorax) had
evidence of chronic inflammatory infiltrate and mesothelial
proliferation and Case 3 (empyema) had acute and chronic
inflammation with fibrosis. Six lncRNAs were detectable. Super-
vised cluster analysis showed that the expression patterns for these
lncRNAs were different between normal pleura and MPM tissues
(Figure 2a). AK130275, AK129685, EF177379 and AF268386 all
demonstrated .-2-fold expression differences in MPM compared
to benign pleura without reaching significance (AK130275 – 3.3
fold, MWU P=0.345; AK129685 – 3.2 fold, MWU P=0.659;
EF177379 – 2.8 fold, MWU P=0.186; AF268386 – 2.17 fold,
MWU P=0.950). The remaining two lncRNAs, BX648695 and
NR_003584 both demonstrated significant expression differences
in MPM compared to benign pleura (BX648695 – 2.95 fold,
MWU P=0.028; NR_003584- 5-fold, MWU P=0.038). Receiver
operating characteristic (ROC) curve analysis showed that
BX648695 could discriminate benign pleura and MPM with an
accuracy of 93%, sensitivity 78.6% and specificity 100% (AUC
0.93, 95% confidence interval 0.793–1.064, P= 0.023; Figure 2b).
Similarly NR_003584 could discriminate benign pleura and MPM
with an accuracy of 90.5%, sensitivity 78.5% and specificity 100%
(AUC 0.905, 95% confidence interval 0.752–1.057, P= 0.033;
Figure 2a). While the remaining lncRNAs did not demonstrate
significant differences between benign pleura and MPM, it does
not exclude these targets as potential markers given the small test
cohort used (Figure 1d).
Identification of lncRNA expression profiles to classify
normal mesothelium and MPM
To determine whether lncRNA expression profiles are capable
of distinguishing normal mesothelium and MPM cells, we
performed class prediction analyses using the six lncRNAs
validated/detected in both (1) the original microarray dataset
and (2) RT-qPCR data from the MPM and benign pleural
samples. These six lncRNAs were able to correctly classify MPM
and MeT-5A at P,0.05, using the NCode microarray data. The
worst performing model was the 3-neighbour algorithm which
correctly classified 80% of samples. While able to correctly classify
all MPM cell lines, it was unable to correctly predict MeT-5A as
normal. In contrast the remaining models were able to correctly
classify 100% of samples with 100% sensitivity and specificity. The
best performing models were the compound covariate, diagonal
linear discriminant analysis and nearest centroid classifiers which
were all capable of clearly distinguishing MPM and MeT-5A at
P=0.056 (based on 1000 permutations of the class label).
Validation of this signature in the RT-qPCR data from the 3
benign pleura and 14 MPM tissues showed that the nearest
centroid and compound covariant predictors (CCP) were the best
performing models correctly classifying 76% of samples with a
sensitivity of 71.4%, specificity 100%, PPV 100% and NPV 43%
(CCP P=0.179, Nearest centroid P=0.169 based on 1000
permutations of the class label). In contrast, the remaining models
correctly classified tumours 59–71% of the time with variable
sensitivity and specificity. Overall, this lncRNA signature had good
sensitivity for detecting MPM however assessment in a larger
cohort is required.
LncRNA expression is associated with nodal stage and
prior treatment with induction chemotherapy
Of the nine technically validated lncRNAs, four candidates
were detected in an independent cohort of fifty-seven archived
FFPE tissues and were correlated with clinical covariates including
age, survival time, T stage, nodal involvement, and previous
induction chemotherapy. We observed no significant relationship
between lncRNA expression and histological subtype.
Higher expression of AK054908 was significantly associated
with metastasis in the ipsilateral bronchopulmonary/hilar lymph
nodes (N1 status; AK054908 P=0.005; Figure 2d) with a trend for
higher expression also observed in AF268386 (P=0.071). Signif-
icantly lower levels of AK130275 and AF268386 were observed in
patients receiving induction chemotherapy (AK130275 induction
chemotherapy = 0.763 vs. no chemotherapy 1.578, P=0.002;
AF268386 induction chemotherapy = 0.956 vs. no chemotherapy
1.685, P=0.033). No significant differences were observed
between candidate lncRNA expression levels and tumour stage,
histology or sex.
Stratification of lncRNA expression levels into high and low
expression groups based on median expression values revealed no
significant survival differences between groups. However, cases
with higher EF177379 (NEAT1) expression demonstrated a trend
towards improved survival compared to cases with expression
levels below the median (low expression 13.3 months (95% CI
5.9–20.6 months) versus high expression group 19.3 months (95%
CI 1.5–37.9 months) P=0.065; Figure 2e)). When stratified by
treatment with/without induction chemotherapy, patients with
higher EF177379 levels had better overall survival when they did
not receive induction chemotherapy (Log-Rank P= 0.019, median
Figure 1. RT-qPCR validation reveals significant lncRNA expression differences in MPM cell lines and fresh-frozen tissue. Levels of
lncRNA expression were normalised to 18S and relative expression levels compared to the average level in the control samples for MPM tissues and
MeT-5A for cell lines using the 22DDCq method. (a) Unsupervised cluster analysis of the top 44 lncRNAs found to be differentially expressed between
MeT-5A and MPM (H226, H28, MSTO, MM05) cell lines using NCode Long Noncoding RNA microarrays. All cell lines were profiled in duplicate. Red =
regions over-expressed, Blue = regions under-expressed. (b) Nine candidate lncRNAs were technically validated in MPM cell lines using RT-qPCR. For
RT-qPCR, lncRNA expression levels were normalised to 18S and are expressed relative to MeT-5A. (c) NR_003548 and BX648695 were significantly
elevated in MPM tissues compared to benign pleura. Turkey box plots have median values represented by the line within the boxes, and the 25th and
75th percentiles represented by the upper and lower lines of the box. (d) 7 candidate lncRNAs were biologically validated in an extended panel of
10MPM cell lines. All candidates demonstrated consistent up-regulation of expression. MPM – Malignant Pleural Mesothelioma, lncRNA – long
noncoding RNA, Ctrl – Benign Pleura, * statistically significant at P,0.05 (two-tailed t-test).
doi:10.1371/journal.pone.0070940.g001
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survival low expression = 9.5 month versus high expression
19.7 months). Lower EF177379 levels were present following
treatment with induction chemotherapy.
Genes co-expressed with lncRNAs are associated with
cellular and metabolic processes
Next, we constructed a coding-noncoding gene network to
investigate potential relationships between the top 6 lncRNAs and
305 mRNAs found to be differentially expressed between MPM
and MeT-5A cell lines. Pearson correlations were used to compare
lncRNA and mRNA expression levels from the microarray. Genes
with correlation co-efficients .0.6 and P-values ,0.05 were taken
for additional pathway analysis to identify ontologies/pathways
associated with lncRNA dysregulation (See Table S3 in File S1 for
correlation coefficients, and Table S4 in File S1 for gene
ontologies).
Assessment of mRNAs co-expressed with AK130275 found
over-enrichment of genes involved in cell death (P=0.049) and
epithelium development (P=0.026). In addition, .50% of
mRNAs were associated with phosphoproteins (P=0.003; 56%
genes) and alternative splicing (P=0.024; 52%). For BX648695,
22 unique genes were co-expressed and were associated with
muscle system processes (P=0.047), calcium ion binding
(P=0.024), metal ion binding (P=0.019) and phosphoproteins
(P=0.016). AF268386 co-expressed mRNAs were significantly
associated with actin-filament based processes (P=0.049), glyco-
lipid metabolism (P=0.045), cell proliferation (P=0.025), cell
cycle (P=0.025), ganglioside metabolic processes (P=0.012), and
Rho GTPase binding (P=0.051) with some of these processes
demonstrating a greater than 10-fold over-enrichment. EF177379
(NEAT1) was found to be co-expressed with 139 mRNAs involved
in processes including cell cycle (P,.001), apoptosis (P,0.001),
cell death (P=0.01), regulation of cyclin-dependent protein
kinases (P=0.046), cell cycle arrest (P=0.028), M phase
(P=0.018) and cytoskeleton reorganisation (P=0.021). Several
of these genes were also associated with non-small cell lung cancer
(NSCLC; KEGG pathway; P=0.010).
Enrichment of cell death (P,0.001), apoptosis (P,0.001),
regulation of apoptosis (P=0.01), regulation of protein kinases
(P=0.04) and cell cycle (P=0.046) related processes were
associated with AK129685 co-expression. Finally, mRNAs co-
expressed with NR_003584 were associated with enrichment of
cellular processes including cell cycle (P,0.001), apoptosis
(P= 0.002), actin cytoskeleton organisation (P,0.001), mitotic cell
cycle (P,0.001), regulation of protein kinase activity (P=0.004),
regulation of transferase activity (P=0.006), cell division
(P=0.021), regulation of phosphorylation (P=0.021), regulation
of phosphate metabolism (P=0.026), and cell morphogenesis
(P=0.046).
Discussion
Since the realisation that non-coding regions of the genome are
functional and not ‘‘junk’’ as previously thought, there have been
numerous studies linking changes in long noncoding RNA
(lncRNA) expression to cancer prompting an increasing interest
in the use of lncRNAs as potential disease biomarkers [7,28–30].
There is however, still a lack of knowledge surrounding the
functional implications of lncRNA dysregulation and the precise
role they play in carcinogenesis. To our knowledge this is the first
systematic study of lncRNA expression profiles in MPM. We have
found that lncRNA expression profiles can distinguish malignant
mesothelium and benign pleura, and that some lncRNAs are
associated with nodal metastasis and long term survival.
T
a
b
le
3
.
C
o
n
t.
M
IC
R
O
A
R
R
A
Y
A
N
A
L
Y
S
IS
T
E
C
H
N
IC
A
L
V
A
L
ID
A
T
IO
N
–
C
E
L
L
L
IN
E
S
1
B
IO
L
O
G
IC
A
L
V
A
L
ID
A
T
IO
N
S
E
T
1
-
D
U
B
L
IN
T
U
M
O
U
R
S
E
T
P
ro
b
e
N
a
m
e
T
a
rg
e
t
ID
S
u
b
cl
a
ss
if
ic
a
ti
o
n
P
-v
a
lu
e
D
ir
e
ct
io
n
o
f
E
x
p
re
ss
io
n
A
b
so
lu
te
F
o
ld
C
h
a
n
g
e
A
b
so
lu
te
F
o
ld
-c
h
a
n
g
e
#
D
ir
e
ct
io
n
o
f
E
x
p
re
ss
io
n
P
-v
a
lu
e
A
b
so
lu
te
F
o
ld
-
ch
a
n
g
e
#
D
ir
e
ct
io
n
o
f
E
x
p
re
ss
io
n
P
-v
a
lu
e
IV
G
N
h
3
3
8
4
7
u
c0
0
2
zj
h
In
te
rg
e
n
ic
0
.0
4
8
d
o
w
n
5
.4
2
2
N
P
-
-
-
-
-
#
N
P
–
n
o
p
ri
m
e
rs
co
u
ld
b
e
d
e
si
g
n
e
d
,
N
D
–
N
o
t
d
e
te
ct
e
d
;
–
n
o
t
fo
llo
w
e
d
u
p
b
io
lo
g
ic
al
ly
d
u
e
to
la
ck
o
f
te
ch
n
ic
al
re
p
lic
at
io
n
o
r
o
ri
g
in
al
p
ri
m
e
rs
n
o
t
d
e
si
g
n
e
d
,
Fo
ld
ch
an
g
e
s
fo
r
ce
ll
lin
e
s
ar
e
e
xp
re
ss
e
d
re
la
ti
ve
to
M
e
T
-5
A
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
7
0
9
4
0
.t
0
0
3
Long Non-Coding RNAs in Mesothelioma
PLOS ONE | www.plosone.org 8 August 2013 | Volume 8 | Issue 8 | e70940
Figure 2. Class prediction profiling using the six biologically validated lncRNAs demonstrates high sensitivity in predicting MPM
class in the NCode Microarray data (data not shown) and cryopreserved MPM and benign pleural tissue. (a) Supervised cluster analysis
shows that this predictor demonstrated overexpression (red areas) in MPM tumours compared to benign pleura. Roc curve analysis shows that (b)
NR_003584 and (c) BX648695 can clearly separate benign tumour and MPM tissue with a high degree of accuracy. (d) AK054908 lncRNA expression is
associated with hilar lymph node metastasis. (e) Higher EF177379 expression is associated with longer survival.
doi:10.1371/journal.pone.0070940.g002
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To investigate lncRNA expression patterns in MPM, we used
whole-genome lncRNA expression microarrays to profile four
MPM cell lines, and the immortalised human mesothelial cell line
MeT-5A. As MPM is a rare tumour, it is often difficult to obtain
enough tissue for research purposes, thus we theorised that if
candidate lncRNAs identified from cell line data could be
validated in MPM tissue, then these candidates were likely to
have a biological role in MPM. While recognising that MPM cell
lines often demonstrate additional changes that reflect their
adjustment to in-vitro conditions, the fact that the candidates were
validated in tumour tissues provides evidence for a biological role
in MPM. We ranked candidate lncRNAs on the basis of statistical
significance (P,0.05) and fold change (.3-fold), and validated
expression using RT-qPCR. We identified a panel of nine
lncRNAs, six which were biologically validated in cell lines and
MPM tissues (AK130275, AK129685, EF177379, BX648695,
NR_003584 and AF268386) and seemed to be diagnostic. In
FFPE tissues from MPM patients four lncRNAs were detectable.
Two of these lncRNAs were associated with nodal metastases and
overall survival. Gene ontology and pathway analyses were
performed on co-expressed mRNA-lncRNA networks to investi-
gate possible biological functions of these lncRNAs.
The lncRNA EF177379 (NEAT1), is located on 11q13.1, a
region reported to be amplified in MPM. It has been implicated in
mRNA transport regulation, is associated with the 39 untranslated
region (39UTR) and is an important structural component of
paraspeckles [31]. NEAT1 has been shown to control the retention
of Alu-containing mRNAs in the nucleus with growing evidence
emerging to suggest that gene expression can be regulated by
retained mature mRNAs [32]. These retained mRNAs may be
inefficiently transported out of the nucleus in paraspeckles.
Considering that cancer cells have altered mechanisms for
nucleoplasmic mRNA transport [33], it is possible that NEAT1
may play a role in regulating this pathway in cancer. It is also
tempting to speculate that its expression may also be regulated by
copy number gains.
AK130275 is a bidirectional lncRNA located antisense to PAX8,
a transcription factor expressed at high levels in the thyroid, that
has an essential role in cell proliferation [34]. Bidirectional
lncRNAs have been shown to exhibit similar expression patterns to
their nearby protein-coding genes and are possibly involved in
similar gene regulatory mechanisms. Immunohistochemical stud-
ies have shown that PAX8 expression can help to distinguish
ovarian cancer and pleural/ peritoneal mesotheliomas [35], with
mesotheliomas demonstrating weak to negative staining of PAX8.
A recent meta-analysis of 15 ovarian cancer studies, reported that
prior exposure to asbestos is associated with an elevated risk of
ovarian cancer [36] with ovarian cancers capable of metastasising
to the pleura [37]. Considering its close proximity to PAX8, it is
possible that AK130275 may regulate expression of PAX8 by
stabilizing the corresponding mRNA or exert its own functional
effects. Such a regulatory mechanism has been described for sense-
antisense pairs which show a partial overlap either in 59UTR [38]
or 39UTR regions [39]. Thus AK130275 could be potentially
useful for the differential diagnosis of primary and metastatic
pleural mesothelioma.
AK054908, also known as the small nucleolar RNA host gene 7
(SNHG7), has been described as a 39UTR/bidirectional lncRNA
and is thought to encode the smaller snoRNAs, SNORA43 and
SNORA17. SnoRNAs guide RNAs for post-translational modifi-
cation, in the process modifying ribosomal RNA and are often
located in introns/exons of coding and noncoding transcripts.
Other cancer pathways including the mTOR pathway have also
been implicated in ribosome biogenesis and have been previously
shown to be important for promoting transcription of ribosomal
RNAs. Ribosome biogenesis is critical for protein synthesis during
cell growth and proliferation [40]. In mesothelioma, inhibition of
this pathway has been shown to inhibit cell invasion, motility and
spreading [40]. Whether overexpression of SNHG7 contributes to
altered ribosomal biogenesis and ultimately cell growth and
proliferation remains to be determined, but it is interesting to note
that we found this gene to be associated with nodal metastasis,
suggesting it may be potentially useful as a prognostic marker.
Finally, AF268386 is a long intergenic lncRNA (or long
intergenic noncoding RNA – lincRNA). Intergenic lncRNAs have
been implicated in a variety of biological processes including cell
cycle regulation and immune surveillance, and often work with
chromatin modifying complexes to influence gene regulation.
Epigenetic changes including DNA methylation have been well
reported in MPM with hypermethylation of E-Cadherin (ECAD;
71.4%), fragile histidine triad (FHIT; 78%), the secreted frizzled
related protein family (SFRPs), RASSF1A (19.5%), DAPK (20%) and
RARB (55.8%) all being implicated in MPM [41,42]. The fact that
these changes occur relatively frequently suggests that regulatory
mechanisms controlling these processes become aberrant during
the carcinogenic process, with lncRNAs being one potential source
of epigenetic disruption.
Next, to better understand the functional impact of these
lncRNAs, we applied a pathways approach to study the
relationship between differentially expressed lncRNAs and
mRNAs. We found that our candidate lncRNAs were co-
expressed with mRNAs involved in a variety of cell processes
including cell death, cell proliferation, apoptosis, glycolipid
metabolism, Rho-GTPase signalling, cell cycle, DNA replication,
recombination and repair, actin cytoskeleton reorganisation and
regulation of the protein kinase cascade. All of these pathways are
key processes involved in cancer progression suggesting that these
lncRNAs may play critical roles in cell cycle regulation. Several of
the mRNAs identified as being differentially expressed in our study
have also been identified in previous MPM gene expression
studies, strengthening the validity and quality of our data, and
highlighting the likely biological role of these candidates
[25,27,43]. Integration of lncRNA expression profiles with mRNA
and microRNAs profiles is likely to provide insights into the
precise roles these lncRNAs are playing. It is possible these
lncRNAs act in negative or positive feedback loops as oncogenes
or tumour suppressor genes.
There is also evidence to suggest that ncRNAs may interact with
microRNAs to form extensive regulatory networks [5]. Termed
competing endogenous RNAs (ceRNA), these ceRNAs can protect
target RNAs from repression by sequestering microRNAs [5]. In
hepatocellular carcinoma (HCC), the maternally expressed gene 3
(MEG3) was found to be hypermethylated and down-regulated by
210-fold in HCC compared to non-malignant hepatocytes.
Investigation of microRNA dependent regulation by miR-29a,
showed that its overexpression was associated with a methylation
dependent and tissue specific increase in MEG3 expression [44].
In muscle differentiation, linc-MD1 contains recognition sites for
miR-133 and miR-135 with its depletion found to reduce levels of
two predicted targets of miR-133 and miR-135, MAML1 and
MEF2C [45]. This suggests that linc-MD1 may act as a decoy for
miR-133 and miR-135. In addition, PTENP1 a lncRNA antisense
to PTEN, shares a similar 39UTR transcript to PTEN [46].
Mutations in this region have been shown to disrupt microRNA
binding, negating the protective effect of the lncRNA transcript,
[46]. Taken together these studies highlight the interdependence
observed between lncRNAs and microRNAs, and suggest that
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lncRNAs and microRNAs work together in complex regulatory
networks to activate or suppress gene expression.
The recent implementation of large scale next-generation
sequencing has provided vast insights into gene regulation, with
accumulating evidence suggesting that lncRNAs have important
functional roles in cancer development. LncRNAs may therefore
be useful diagnostic and prognostic biomarkers especially given
their higher tissue specificity. For example the non-coding RNA
prostate cancer antigen 3 (PCA3) has been shown to improve the
diagnosis of prostate cancer in a more sensitive and specific
manner than the widely used PSA (prostate-specific antigen), and is
detectable in urine from patients with prostate cancer [47] while,
the highly upregulated in liver cancer (HULC) lncRNA has been
detected in blood from patients with hepatocellular carcinoma
(HCC) [48]. Many lncRNAS have also been implicated in the
control of metastasis, apoptosis and drug resistance including
MALAT1 which has been shown to be prognostic in early-stage
lung adenocarcinoma and HOTAIR [49] which correlates with
poor outcome and metastases in breast cancer [50] and
nasopharyngeal carcinoma [51] and tumour recurrence in
hepatocellular carcinoma [11]. Finally the cancer upregulated
drug resistant (CUDR) lncRNA, has demonstrated resistance to
doxorubicin and etoposide, enhancing drug induced apoptosis
following stable transfection [52]. These studies demonstrate the
potential for lncRNAs to be used as prognostic and diagnostic
markers in cancer.
Here, we identified a panel of lncRNAs that was capable of
distinguishing benign mesothelium and MPM tissue with relatively
high sensitivity (71.4%) and specificity (100%). In the cell lines
studied, this panel had a sensitivity and specificity of 100%. In a
study including 200 MPM cases, Klebe et. al. demonstrated that
calretinin together with CD15 and BG8 were sensitive and specific
enough to correctly classify all cases [53]. In comparison with
other mesothelial markers including WT1, the lncRNA panel has
higher specificity. Molecular panels such as the one reported here
can provide great insights into the molecular changes occurring in
the tumour and may turn out to be useful for screening
purposesummary, we show that lncRNA expression is dysregulat-
ed in MPM compared with normal mesothelium, in what is to the
best of our knowledge the first study of its kind. Our profiling
studies revealed that AK130275, AK129685, EF177379,
BX648695, NR_003584 and AF268386 are substantially up-
regulated in MPM tumours compared to benign pleura, and are
detectable in both FFPE and fresh-frozen MPM tissues. We also
demonstrate that lncRNAs have potential prognostic and diag-
nostic utility. Further work is required to evaluate whether these
lncRNAs are capable of differentiating malignant mesothelioma
from lung cancer and benign asbestos-related diseases, and to
reveal their specific functions in MPM pathogenesis.
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